QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Erratum An erratum has been published All Versions of this Article: jpet.107.132233v1 326/1/218    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lehto, S. G. Articles by Gavva, N. R. Search for Related Content PubMed PubMed Citation Articles by Lehto, S. G. Articles by Gavva, N. R.

NEUROPHARMACOLOGY

Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats

Departments of Neuroscience (S.G.L., R.T., H.D., L.K., R.K., A.L., D.L., J.-C.L., E.M., B.H.M., J.R., T.W., Jud.W., Jue.W., W.W., B.Y., M.Z., D.Z., N.R.G.), Chemistry Research and Discovery (N.T., M.H.N.), and Pharmacokinetics and Drug Metabolism (S.S.), Amgen Inc., Thousand Oaks, California

Antagonists of the vanilloid receptor TRPV1 (transient receptor potential vanilloid type 1) have been reported to produce antihyperalgesic effects in animal models of pain. These antagonists, however, also caused concomitant hyperthermia in rodents, dogs, monkeys, and humans. Antagonist-induced hyperthermia was not observed in TRPV1 knockout mice, suggesting that the hyperthermic effect is exclusively mediated through TRPV1. Since antagonist-induced hyperthermia is considered a hurdle for developing TRPV1 antagonists as therapeutics, we investigated the possibility of eliminating hyperthermia while maintaining antihyperalgesia. Here, we report four potent and selective TRPV1 modulators with unique in vitro pharmacology profiles (profiles A through D) and their respective effects on body temperature. We found that profile C modulator, (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)acrylamide (AMG8562), blocks capsaicin activation of TRPV1, does not affect heat activation of TRPV1, potentiates pH 5 activation of TRPV1 in vitro, and does not cause hyperthermia in vivo in rats. We further profiled AMG8562 in an on-target (agonist) challenge model, rodent pain models, and tested for its side effects. We show that AMG8562 significantly blocks capsaicin-induced flinching behavior, produces statistically significant efficacy in complete Freund's adjuvant- and skin incision-induced thermal hyperalgesia, and acetic acid-induced writhing models, with no profound effects on locomotor activity. Based on the data shown here, we conclude that it is feasible to modulate TRPV1 in a manner that does not cause hyperthermia while maintaining efficacy in rodent pain models.

Address correspondence to: Dr. Narender R. Gavva, Department of Neuroscience, MS-29-2-B, One Amgen Center Dr., Thousand Oaks, CA 91320-1799. E-mail: ngavva{at}amgen.com

This article has been cited by other articles:

				B. Fioravanti, M. De Felice, C. L. Stucky, K. A. Medler, M.-C. Luo, L. R. Gardell, M. Ibrahim, T. P. Malan Jr, H. I. Yamamura, M. H. Ossipov, et al. Constitutive Activity at the Cannabinoid CB1 Receptor Is Required for Behavioral Response to Noxious Chemical Stimulation of TRPV1: Antinociceptive Actions of CB1 Inverse Agonists J. Neurosci., November 5, 2008; 28(45): 11593 - 11602. [Abstract] [Full Text] [PDF]